90 completed. 90 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 90 | Completed 90 |
| Phase 2 | 12 | Completed 12 |
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects HRS-9813 Capsule, Nintedanib Soft Capsules, Pirfenidone Tablets - Pulmonary Fibrosis | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 20 | 2026-04-04 | 2026-09-21 |
| A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis MNKD-201(Nintedanib DPI), Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 1 | Completed | Mannkind Corporation | 27 | 2025-12-22 | 2026-07-22 |
| A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants GNS-3545, GNS-3545 Placebo - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Genosco Inc. | 63 | 2025-11-12 | 2026-07-17 |
| NAL ER IPF Respiratory Function and Safety Study NAL ER, Placebo - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Trevi Therapeutics | 9 | 2025-08-21 | 2026-08-03 |
| A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects HRS-9813 Capsule, HRS-9813 Tablet - Pulmonary Fibrosis | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 12 | 2025-05-04 | 2025-07-08 |
| A Trial of HRS-9813 in Healthy Subjects HRS-9813 - Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 45 | 2025-02-17 | 2026-07-02 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 Exposure CHF10073 (Part 1 - SAD), Placebo (Part 1 - SAD), CHF10073 (Part 2 - MAD) - Pulmonary Fibrosis | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 155 | 2025-01-13 | 2026-02-12 |
| Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib Nintedanib 150 MG [Ofev] - Drug Interactions | Phase 1 | Completed | PureTech | 24 | 2024-12-17 | 2026-08-13 |
| PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF PIPE-791 - Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Contineum Therapeutics | 16 | 2024-12-09 | 2025-08-06 |
| A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib Part A: Placebo, Nintedanib, GSK3915393 - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | GlaxoSmithKline | 50 | 2024-10-07 | 2025-02-18 |
| Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets in Healthy Subjects Under Fasting and Fed Conditions Pirfenidone Modified-Release Tablets - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Overseas Pharmaceuticals, Ltd. | 18 | 2024-09-18 | 2025-03-20 |
| Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis CMR316, Placebo - Pulmonary Fibroses, Idiopathic | Phase 1 | Completed | Calibr, a division of Scripps Research | 89 | 2024-08-19 | 2026-07-09 |
| A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants AZD8965, Placebo - Healthy Participants | Phase 1 | Completed | AstraZeneca | 147 | 2024-08-02 | 2025-12-11 |
| Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment Mesenchymal Stem Cells from Wharton´s jelly - Systemic Sclerosis Pulmonary, Pulmonary Hypertension | Phase 1 / Phase 2 | Completed | Fundación Neumologica Colombiana | 1 | 2024-05-15 | 2026-04-21 |
| Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions Pirfenidone Modified-Release Tablets, Pirfenidone Tablets - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Overseas Pharmaceuticals, Ltd. | 12 | 2024-04-08 | 2024-09-19 |
| Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF) VUM02 Injection - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | 9 | 2024-03-05 | 2026-07-31 |
| Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect EGCG 300 mg, Placebo for EGCG 300 mg, EGCG 600 mg - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Hal Chapman | 12 | 2024-02-07 | 2026-04-14 |
| The First-in-human Study of SRN-001 in Healthy Participants SRN-001, Placebo - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | siRNAgen Therapeutics Inc. | 25 | 2023-09-08 | 2024-11-04 |
| Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions Pirfenidone Modified-Release Tablets, Pirfenidone Tablets - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Overseas Pharmaceuticals, Ltd. | 24 | 2023-08-25 | 2024-09-19 |
| Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Hal Chapman | 50 | 2023-08-24 | 2026-04-14 |
Showing 20 of 90. Sign in to see all of them.
Idiopathic Pulmonary Fibrosis (77) · Lung Diseases (5) · Fibrosis (4) · Lung Diseases, Interstitial (4) · Hypertension, Pulmonary (3) · Anemia, Aplastic (2) · Idiopathic Interstitial Pneumonias (2) · Liver Cirrhosis (2) · Pathologic Processes (2) · Pulmonary Disease, Chronic Obstructive (2) · Respiratory Tract Diseases (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Bone Marrow Failure Disorders (1)
Respiratory Tract Diseases (88) · Lung Diseases, Interstitial (86) · Lung Diseases (85) · Pathological Conditions, Signs and Symptoms (24) · Pathologic Processes (22) · Fibrosis (18) · Digestive System Diseases (4) · Cardiovascular Diseases (3) · Chronic Disease (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Disease Attributes (3) · Genetic Diseases, Inborn (3) · Hypertension (3) · Skin Diseases (3)
pirfenidone (11) · nintedanib (7) · Itraconazole (2) · epigallocatechin gallate (2) · ATX inhibitor BBT-877 (1) · Albuterol (1) · BI 1015550 (1) · CC-90001 (1) · Capsules (1) · Carbamazepine (1) · Control Groups (1) · Danazol (1) · Dasatinib (1) · Exercise (1) · Gemfibrozil (1)
Bristol-Myers Squibb (5) · Sunshine Lake Pharma Co., Ltd. (5) · GlaxoSmithKline (4) · Guangdong Hengrui Pharmaceutical Co., Ltd (4) · Daewoong Pharmaceutical Co. LTD. (3) · Overseas Pharmaceuticals, Ltd. (3) · AstraZeneca (2) · Chiesi Farmaceutici S.p.A. (2) · Guangzhou JOYO Pharma Co., Ltd (2) · Hal Chapman (2) · Hoffmann-La Roche (2) · Rein Therapeutics (2) · Arrowhead Pharmaceuticals (1) · Bastiaan Driehuys (1) · Bellerophon (1)
United States (34) · China (18) · United Kingdom (12) · Australia (9) · Belgium (4) · Germany (4) · South Korea (4) · Spain (4) · Canada (3) · Denmark (2) · France (2) · Italy (2) · Netherlands (2) · New Zealand (2) · Taiwan (2)
Yu Cao, Doctor (2) · Ana Beatriz Hortense, MD (1) · Annelize Koch (1) · Ashika Ahmed (1) · Bastiaan Driehuys, Ph.D. (1) · Bruno Crestani, MD, PhD (1) · Cao Yu, Doctor (1) · Carlos Lopez, MD (1) · Christopher J Wynne, MBChB (1)
PMID 16883006, PMID 22379151, PMID 26869678, PMID 27103349, PMID 27192671, PMID 29409488, PMID 30616998, PMID 32026407, PMID 32160670, PMID 33214209, PMID 33463535, PMID 33472968, PMID 33740394, PMID 34195252, PMID 35667792, PMID 36579443, PMID 37116909, PMID 37738329, PMID 42538332
2015 (1), 2017 (1), 2023 (1), R01HL126771 (1), R33HL158540 (1)